Ibrutinib, a brain-penetrant BTK inhibitor originally designed to treat B-cell lymphoma, was administered to 5xFAD and PS19 transgenic mice and was found to suppress Aβ and tau pathology and neuroinflammation, as well as increase the number of dendritic spines on hippocampal neurons, indicating it as a potential treatment for AD patients. This evidence concerns the gene MAPT and Alzheimer disease.